Encompass Health Corporation $EHC Shares Sold by Avidity Partners Management LP

Avidity Partners Management LP trimmed its stake in shares of Encompass Health Corporation (NYSE:EHC) by 24.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 31,600 shares of the company’s stock after selling 10,300 shares during the quarter. Encompass Health comprises 1.0% of Avidity Partners Management LP’s portfolio, making the stock its 22nd largest position. Avidity Partners Management LP’s holdings in Encompass Health were worth $3,354,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in EHC. WPG Advisers LLC increased its position in Encompass Health by 73.3% in the 4th quarter. WPG Advisers LLC now owns 324 shares of the company’s stock valued at $34,000 after acquiring an additional 137 shares during the period. Flagship Harbor Advisors LLC acquired a new stake in Encompass Health in the 4th quarter valued at approximately $37,000. Assetmark Inc. increased its position in Encompass Health by 88.1% in the 3rd quarter. Assetmark Inc. now owns 299 shares of the company’s stock valued at $38,000 after acquiring an additional 140 shares during the period. Caitong International Asset Management Co. Ltd increased its position in Encompass Health by 36,200.0% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 363 shares of the company’s stock valued at $46,000 after acquiring an additional 362 shares during the period. Finally, Covestor Ltd increased its position in Encompass Health by 24.4% in the 4th quarter. Covestor Ltd now owns 540 shares of the company’s stock valued at $57,000 after acquiring an additional 106 shares during the period. 97.25% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts recently commented on EHC shares. Leerink Partners set a $152.00 target price on Encompass Health in a research report on Friday, May 22nd. Wall Street Zen upgraded Encompass Health from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. TD Cowen started coverage on Encompass Health in a research report on Thursday, May 28th. They issued a “buy” rating and a $125.00 target price on the stock. Weiss Ratings restated a “buy (b-)” rating on shares of Encompass Health in a research report on Monday, June 8th. Finally, Barclays lowered their target price on Encompass Health from $153.00 to $140.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 5th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $143.86.

Encompass Health Stock Performance

Shares of NYSE EHC opened at $101.49 on Friday. The stock has a fifty day moving average price of $104.31 and a two-hundred day moving average price of $104.65. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.17 and a current ratio of 1.17. The firm has a market cap of $10.07 billion, a P/E ratio of 16.94, a PEG ratio of 2.21 and a beta of 0.72. Encompass Health Corporation has a 1 year low of $92.77 and a 1 year high of $127.99.

Encompass Health (NYSE:EHC) last issued its quarterly earnings results on Thursday, April 30th. The company reported $1.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.51 by $0.09. The firm had revenue of $1.59 billion during the quarter, compared to analyst estimates of $1.57 billion. Encompass Health had a return on equity of 18.28% and a net margin of 10.04%.The firm’s quarterly revenue was up 9.0% on a year-over-year basis. During the same period last year, the company posted $1.37 EPS. Encompass Health has set its FY 2026 guidance at 5.890-6.110 EPS. Research analysts forecast that Encompass Health Corporation will post 5.97 EPS for the current fiscal year.

Encompass Health Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, July 15th. Shareholders of record on Wednesday, July 1st will be paid a dividend of $0.19 per share. This represents a $0.76 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date of this dividend is Wednesday, July 1st. Encompass Health’s dividend payout ratio (DPR) is presently 12.69%.

Insider Transactions at Encompass Health

In other Encompass Health news, EVP Patrick William Tuer sold 682 shares of the stock in a transaction on Monday, May 11th. The stock was sold at an average price of $104.56, for a total transaction of $71,309.92. Following the completion of the transaction, the executive vice president directly owned 24,755 shares of the company’s stock, valued at approximately $2,588,382.80. This trade represents a 2.68% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 1.80% of the company’s stock.

About Encompass Health

Encompass Health Corporation is a leading provider of post‐acute healthcare services in the United States, operating a comprehensive network of inpatient rehabilitation hospitals and home health and hospice agencies. Its inpatient rehabilitation hospitals offer intensive therapy programs for patients recovering from conditions such as stroke, brain injury, spinal cord injury, cardiac and pulmonary disorders, and orthopedic procedures. Through its home health segment, Encompass Health delivers skilled nursing, physical therapy, occupational therapy and speech therapy to patients in the comfort of their homes, while its hospice services provide end‐of‐life care focused on symptom management and emotional support for patients and families.

Founded in 1984 as HealthSouth Corporation and rebranded as Encompass Health in 2018, the company has grown organically and through acquisitions to serve patients across more than 30 states.